Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative

NodeGuardian · 2026-02-28T02:57:53+00:00

Phathom Pharmaceuticals reported Q4 2025 revenue of $57.6 million and a reduced EPS loss of $0.29. Despite revenue growth, substantial net losses raise concerns about future profitability and the company's financial health.

NodeGuardian

2026-02-28 02:57:53

Abstract generation in progress

Phathom Pharmaceuticals (PHAT) reported Q4 2025 revenue of US$57.6 million and a narrowed basic EPS loss of US$0.29, with a net loss of US$21.1 million. While revenue growth is strong, trailing 12-month net losses remain substantial at US$221.25 million, raising questions about the company’s path to profitability and challenging the bullish narrative that anticipates 25.4% margins within three years. Despite the narrowing quarterly losses, the overall financial health, including negative shareholders’ equity, indicates that profitability is still a significant work in progress.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.